Company intelligence / Profile preview

NeXeption

Malvern, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

NeXeption enables the creation and development of subsidiary companies with clinical assets that have demonstrated phase II proof-of-concept in indications like overactive bladder (solabegron) and topical LXR agonists for skin disorders. Programs are advanced to value-inflection points then often acquired by strategic partners or larger pharma companies, with successful exits documented.

Therapeutic areas: UrologyDermatologyGastroenterology
Modalities: Small moleculeBiologic
Industry: Investors

Partnerships

New Science VenturesThird Point VenturesPalo Alto Investors

Beyond the preview

Go deeper on NeXeption.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeXeption.

Explore the full profile